CorMedix (CRMD) Non-Current Deffered Revenue (2010 - 2015)
CorMedix (CRMD) posted Non-Current Deffered Revenue of $28878.0 for Q4 2015, up 163.65% sequentially from $10953.0 in Q1 2013.
CorMedix (CRMD) Non-Current Deffered Revenue (2010 - 2015) Analysis & Trends
CorMedix has reported Non-Current Deffered Revenue for 5 years, with the latest figure at $28878.0 in Q4 2015.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $28878.0 in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $28878.0 (changed N/A YoY) and the FY2015 annual result came in at $28878.0, changed N/A from the prior year.
- Non-Current Deffered Revenue rose to $28878.0 in Q4 2015 per CRMD's latest filing, from $10953.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $28878.0 in Q4 2015 and troughed at $10953.0 in Q1 2013.
- A 4-year average of $15236.9 and a median of $13900.0 in 2012 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2011 and 2013: Non-Current Deffered Revenue dropped 13.65% in 2011, then slipped 21.2% in 2013.
- Over 4 years, Non-Current Deffered Revenue stood at $14472.0 in 2011, then dropped by 15.8% to $12185.0 in 2012, then slipped by 10.11% to $10953.0 in 2013, then surged by 163.65% to $28878.0 in 2015.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $28878.0, $10953.0, and $12185.0 for Q4 2015, Q1 2013, and Q4 2012 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 28,878.00 |
| Mar 31, 2013 | 10,953.00 |
| Dec 31, 2012 | 12,185.00 |
| Sep 30, 2012 | 12,756.00 |
| Jun 30, 2012 | 13,328.00 |
| Mar 31, 2012 | 13,900.00 |
| Dec 31, 2011 | 14,472.00 |
| Sep 30, 2011 | 15,044.00 |
| Jun 30, 2011 | 15,616.00 |
| Dec 31, 2010 | 16,759.00 |